… A phase I trial to determine the optimal biological dose of celecoxib when combined with
erlotinib in advanced non-small cell lung cancer. Clinical …

… Our recent study reported on the combination of Celecoxib … finding indicated an additive
mechanism of Celecoxib and … Citation2014), however, to the best of our knowledge, this is the …

… Non-small cell lung cancer (NSCLC), including its three … therapy focusing on the combination
of celecoxib (400mg twice … A better understanding of the molecular biology of lung cancer …

… present study the majority of patients received a combination of a … is a maximum of 400 mg
per day, and that higher doses may … finding was obtained in a smaller phase II study for breast …

… trials are also evaluating the combination of celecoxib with … and therapy of non-small cell
lung cancer (NSCLC). … PS 0 to 2 Celecoxib twice daily in escalating doses plus erlotinib 150 mg …

… Reckamp KL, Krysan K, Morrow JD, et al: A phase I trial to determine the optimal biological
dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin …

… Preliminary results of a phase II trial of docetaxel plus celecoxib in pretreated NSCLC …
Probably, the optimal methodology for clinical trials and the best way to combine biologic and …

… Celecoxib was observed to induce lung cancer cell apoptosis … Our study also proved that
COX-2 inhibitors combined with first-… effectively reduce the risk of diarrhea caused by erlotinib. …

… advanced non-small ceil lung cancer (NSCLC). Numerous … Notably, a combination of weekly
docetaxel with celecoxib … Intermittent erLotinib in combination with docetaxeL (DOC): phase …

… determined 48 h after treatment with sorafenib and celecoxib … erlotinib, could increase the
inhibitory effect on NSCLC cells … To the best of our knowledge, the results of the present study …